Role of 18F-FDG PET/CT in Gastric Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05687552

Enrollment

Registered

2023-01-18

Start date

2023-01-31

Completion date

2024-01-31

Last updated

2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.

Detailed description

gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT in staging and restaging of gastric cancer. According to evidence-based data, this modality can evaluate gastric cancer more accurately and is helpful for evaluation of tumor biologic characteristics, detection of lymph node and distant metastases, assessment of tumor response to therapy(9). retrospective and prospective study will conducted at Sohag oncology hospital, nuclear medicine unit& Assuit university hospital, nuclear medicine unit including 50 patients in 12 months .

Interventions

DEVICEpet -ct

assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

1. patients diagnosed as GC on surgically resected specimens; 2. Patients with gastric and extragastric metastasis. 3. patients with gastric cancer either operated or not.

Exclusion criteria

1. Patients with second malignancy. 2. Patient without proven pathology of cancer stomach. 3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging). 4. uncontrolled diabetic patient with blood glucose level more than 200mg\\dl. 5. pregnant women

Design outcomes

Primary

Measure	Time frame	Description
comparison of pet -ct finding with ct finding	base line	The 18F-FDG PET/CT scan is visually estimated in the patients included in the study and quantitatively assessed by estimation of standardized uptake value(suv max). Statistical analysis of the included quantitative data.

Contacts

Primary Contactsara saber, ass lec

jasmenahmed90@gmail.com01097661576

Backup Contactwaleed diab, ass prof

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026